Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasm Metastasis 4Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Solid Tumor Malignancies 1Carcinoma, Non-Small-Cell Lung 1Advanced or Recurrent Solid Tumors 1

Interventions

Irinotecan 30Gemcitabine 25Paclitaxel 24Cisplatin 24Docetaxel 19Oxaliplatin 15Fluorouracil 15alvocidib 13Leucovorin 13Carboplatin 12Capecitabine 12Bortezomib 10Taxes 83-aminopyridine-2-carboxaldehyde thiosemicarbazone 7ixabepilone 6Vorinostat 6Topotecan 6Temozolomide 6Immunohistochemistry 6Immunoenzyme Techniques 6Bevacizumab 67-hydroxystaurosporine 6tanespimycin 5Sorafenib 5Pharmacogenomic Testing 5Pemetrexed 5Etoposide 5Chromatography, High Pressure Liquid 57-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine 5temsirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unspecified Adult Solid Tumor, Protocol Specific × vadimezan × Clear all
NCT00003697 2013-12-19

Dimethylxanthenone Acetic Acid in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
3 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡